Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Open Vet J ; 12(1): 23-32, 2022.
Artigo em Inglês | MEDLINE | ID: mdl-35342727

RESUMO

Background: During early life, exposure to environmental toxicants, including endocrine disruptor bisphenol A (BPA), can be detrimental to the immune system. To our knowledge, a few researches have looked at the effects of developing BPA exposures on the spleen. Aim: The murine model was developed to investigate the underlying molecular mechanisms and mode of BPA actions on the spleen subsequent to prolonged early-life exposure to BPA. Methods: Immature (3-week-old) male and female Swiss Albino mice were intraperitoneally injected with 50 µg/kg BPA in corn oil or corn oil alone for 6 weeks. Mouse spleens were harvested and examined histologically at 10 weeks old (adulthood). Results: We observed neurobehavioral impairments and a significant increase in peripheral monocyte and lymphocyte counts in mice (males and females). Moreover, several spleen abnormalities in both male and female mice were observed in adulthood. BPA-treated mice's histopathological results revealed toxicity in the form of significantly active germinal centers of the white pulp and a few apoptotic cells. There was also a notable invasion of the red pulp by eosinophils and lymphocytes that were significantly higher than normal. Agarose gel electrophoresis provided further evidence of internucleosomal DNA fragmentation and apoptosis in the splenic tissues of BPA-treated mice compared to controls. In addition, there were increased levels of the lipid peroxidation malondialdehyde end-product, a marker of oxidative lipid damage, in the spleens of BPA-treated mice compared to controls. Conclusion: Our study provides evidence that oxidative stress injury induced by early-life exposures to BPA could contribute to a range of splenic tissue damages during adulthood.


Assuntos
Óleo de Milho , Baço , Animais , Compostos Benzidrílicos/toxicidade , Óleo de Milho/farmacologia , Feminino , Masculino , Camundongos , Estresse Oxidativo , Fenóis
2.
Immun Inflamm Dis ; 5(2): 190-199, 2017 06.
Artigo em Inglês | MEDLINE | ID: mdl-28474502

RESUMO

INTRODUCTION: As manuka honey (MH) exhibits immunoregulatory and anti-staphylococcal activities, we aimed to investigate if it could be effective in the treatment of atopic dermatitis (AD). METHODS: Adult volunteers with bilateral AD lesions were asked to apply MH on one site overnight for seven consecutive days and leave the contralateral site untreated as possible. Three Item Severity score was used to evaluate the response. Skin swabs were obtained from both sites before and after treatment to investigate the presence of staphylococci and enterotoxin production. In addition, the ability of MH and its methanolic and hexane extracts to down regulate IL4-induced CCL26 protein release from HaCaT cells was evaluated by enzyme linked immunosorbent assay. Also, the ability of MH to modulate calcium ionophore-induced mast cell degranulation was assessed by enzyme immunoassay. RESULTS: In 14 patients, AD lesions significantly improved post MH treatment versus pre-treatment as compared to control lesions. No significant changes in the skin staphylococci were observed after day 7, irrespective of honey treatment. Consistent with the clinical observation, MH significantly down regulated IL4-induced CCL26 release from HaCaT cells in a dose-dependent manner. This effect was partially lost, though remained significant, when methanolic and hexane extracts of MH were utilized. In addition, mast cell degranulation was significantly inhibited following treatment with MH. CONCLUSIONS: MH is potentially effective in the treatment of AD lesions based on both clinical and cellular studies through different mechanisms. This needs to be confirmed by randomized and controlled clinical trials.


Assuntos
Degranulação Celular/efeitos dos fármacos , Quimiocina CCL26/imunologia , Dermatite Atópica/tratamento farmacológico , Mel , Interleucina-4/imunologia , Mastócitos/imunologia , Adulto , Degranulação Celular/imunologia , Linhagem Celular , Dermatite Atópica/imunologia , Dermatite Atópica/patologia , Feminino , Humanos , Masculino , Projetos Piloto
3.
J Clin Pathol ; 67(11): 949-54, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25232128

RESUMO

AIMS: Extending work with brain tumours, the hypothesis that micronutrients may usefully augment anticancer regimens, chokeberry (Aronia melanocarpa) extract was tested to establish whether it has pro-apoptotic effects in AsPC-1, an established human pancreatic cell line, and whether it potentiates cytotoxicity in combination with gemcitabine. Pancreatic cancer was chosen as a target, as its prognosis remains dismal despite advances in therapy. METHODS: An MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay was used to assess the growth of the single pancreatic cancer cell line AsPC-1, alone and in comparison or combination with gemcitabine. This was backed up by flow cytometric DRAQ7 cell viability analysis. TUNEL assays were also carried out to investigate pro-apoptotic properties as responsible for the effects of chokeberry extract. RESULTS: Chokeberry extract alone and its IC75 value (1 µg/mL) in combination with gemcitabine were used to assess the growth of the AsPC-1 cell line. Gemcitabine in combination with chokeberry extract was more effective than gemcitabine alone. TUNEL assays showed apoptosis to be a mechanism occurring at 1 µg/mL concentration of chokeberry, with apoptotic bodies detected by both colourimetric and fluorometric methods. CONCLUSIONS: The implication of this study, using single cancer cell line, is that chemotherapy (at least with gemcitabine) might be usefully augmented with the use of micronutrients such as chokeberry extract.


Assuntos
Adenocarcinoma/patologia , Antineoplásicos Fitogênicos/farmacologia , Protocolos de Quimioterapia Combinada Antineoplásica/farmacologia , Desoxicitidina/análogos & derivados , Neoplasias Pancreáticas/patologia , Photinia , Polifenóis/farmacologia , Antineoplásicos Fitogênicos/isolamento & purificação , Apoptose/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Colorimetria , Desoxicitidina/farmacologia , Relação Dose-Resposta a Droga , Sinergismo Farmacológico , Citometria de Fluxo , Humanos , Marcação In Situ das Extremidades Cortadas , Photinia/química , Fitoterapia , Plantas Medicinais , Polifenóis/isolamento & purificação , Gencitabina
4.
Br J Clin Pharmacol ; 72(4): 593-603, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21752066

RESUMO

Conventional anticoagulants have proven efficacy in the management of thromboembolism. Their adverse effects and a narrow therapeutic window, necessitating regular need for monitoring, however, have long been an incentive for the development of safer anticoagulants without compromising efficacy. Over the last decade or so several new parenteral and oral anticoagulants have been launched with efficacy comparable with conventional agents. From fondaparinux to its long acting derivative idraparinux, and the factor Xa inhibitor rivaroxaban to the direct thrombin inhibitor dabigatran, the advent of new anticoagulants is radically changing anticoagulation. For conventional anticoagulants, despite their shortcomings, effective methods of reversing their anticoagulant effects exist. Moreover, strategies to deal with the occurrence of fresh thrombotic events in the face of therapeutic anticoagulation with the conventional agents have also been addressed. Nevertheless, for the new anticoagulants, the optimal management of these complications remains unknown. This review explores these issues in the light of current evidence.


Assuntos
Anticoagulantes/efeitos adversos , Benzimidazóis/efeitos adversos , Hemorragia/induzido quimicamente , Morfolinas/efeitos adversos , Tiofenos/efeitos adversos , Tromboembolia/tratamento farmacológico , Trombose/tratamento farmacológico , beta-Alanina/análogos & derivados , Dabigatrana , Humanos , Rivaroxabana , Falha de Tratamento , beta-Alanina/efeitos adversos
5.
BJU Int ; 99(6): 1456-60, 2007 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-17484766

RESUMO

OBJECTIVE: To investigate whether lycopene levels in blood and seminal plasma increase after dietary supplementation with a natural source of the compound, and whether any potential increase of lycopene levels in semen translates into increased free-radical trapping capacity in the seminal plasma. METHODS: Reactive oxygen species are detrimental to the health and function of spermatozoa. Semen contains enzymatic and non-enzymatic defence mechanisms to combat such species, and lycopene, a dietary antioxidant, forms part of the non-enzymatic arm. Immuno-infertile men have significantly lower levels of lycopene in their semen, and oral lycopene therapy can improve various seminal variables in idiopathic infertility. Whether this improvement is a direct consequence of increased lycopene levels in semen, resulting in an increased radical scavenging ability, remains unknown. Blood and seminal lycopene levels were measured in healthy volunteers, using high-performance liquid chromatography, before and after a period of dietary supplementation. The antioxidant capacity of seminal plasma was also assayed to determine if supplementation results in a measurable increase in seminal radical scavenging ability. RESULTS: There were statistically significant increases in blood and seminal plasma lycopene levels after dietary supplementation. The increase in seminal and blood lycopene levels showed a strong positive correlation (r = 0.84, P < 0.05). There was no measurable increase in the total radical scavenging capacity of semen. CONCLUSION: This study confirms the presence of lycopene in human semen, the levels of which can be significantly increased after dietary supplementation with a natural source of lycopene. Further studies to establish whether this would also be the case in infertile men, with possible associated improvements in their seminal quality, are warranted.


Assuntos
Antioxidantes/metabolismo , Carotenoides/metabolismo , Suplementos Nutricionais , Infertilidade Masculina/dietoterapia , Sêmen/química , Adulto , Antioxidantes/uso terapêutico , Carotenoides/sangue , Carotenoides/uso terapêutico , Cromatografia Líquida de Alta Pressão , Humanos , Licopeno , Masculino , Espécies Reativas de Oxigênio/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA